Dr. Girard Discusses Results From PALOMA-2

Nicolas Girard, MD, PhD, of Institut Curie in Paris, France, joined Lung Cancers Today to discuss and share insights from PALOMA-2, which explored subcutaneous amivantamab in advanced non-small cell lung cancer (NSCLC) and was presented at the 2025 European Lung Cancer Congress (ELCC).

The study followed results from PALOMA-3, which demonstrated that subcutaneous amivantamab reduced administration-related reactions and showed noninferior efficacy compared to intravenous amivantamab. PALOMA-2 evaluated subcutaneous amivantamab across various EGFR-mutated NSCLC settings and experiences of switching to subcutaneous after intravenous monotherapy.

“It was interesting to see that in PALOMA-2, we have multiple cohorts depending on the setting in terms of previous treatments, type of EGFR mutant, non-small cell lung cancer, combination with lazertinib, or even chemotherapy,” Dr. Girard explained. “In the cohort that was presented at ELCC, 26 patients were enrolled in this amivantamab single-agent cohort, number 4.”

The patients in cohort 4 received subcutaneous amivantamab after receiving the intravenous formulation. Dr. Girard explained that the duration of subcutaneous amivantamab was more than 7 months, while the patients received only 3 months of intravenous therapy. The researchers also administered a questionnaire to assess the impact of each formulation on physical functioning, psychological functioning, and other dimensions of quality of life.

“The results show that the safety profile was quite similar across the two arms,” he said. “And if we look at the quality-of-life assessment, it was better with a subcutaneous formulation in all the dimensions. And when amivantamab [intravenous] was seen in about 25% of the patients as being associated with some inconvenience, we see that with the switch to subcutaneous, we do not have this reporting from the patient.”

Dr. Girard emphasized that these results support switching the standard formulation of amivantamab to subcutaneous for many patients.

“It’s clear now that we have to integrate [this formulation] into clinical practice,” Dr. Girard said. “It also opens the window for at-home administration of amivantamab, and this should even facilitate the quality of life of patients. We had previous reports regarding the subcutaneous formulation being less associated with infusion-related reactions, possibly associated with more prolonged duration of treatment in combination with lazertinib, and also, some data showed more limited subcutaneous side effects. The subcutaneous formulation has many advantages and probably would be prioritized at some point by the prescribers.”